Clopidogrel pathway

[11] Herbert Jean-Marc, 2003, Semin Vasc Med, V3, P113

[12] Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (09): : 937 - 944

[13] Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects [J]. BLOOD, 2006, 108 (07) : 2244 - 2247

[14] Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (01) : 92 - 99

[15] Clopidogrel and Calcium-Channel Antagonists Another Drug-Drug Interaction for the Ever-Wary Clinician? [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (19) : 1564 - 1566

[16] Kurihara A., 2005, DRUG METAB REV S2, V37, P99

[17] Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction [J]. CIRCULATION, 2003, 107 (01) : 32 - 37

[18] Levin L S, 1981, J Md State Dent Assoc, V24, P21

[19] Lins R, 1999, SEMIN THROMB HEMOST, V25, P29

[20] High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients - A Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis [J]. AMERICAN HEART JOURNAL, 2008, 155 (05) : 954 - 958

[11] Herbert Jean-Marc, 2003, Semin Vasc Med, V3, P113

[12] Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (09): : 937 - 944

[13] Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects [J]. BLOOD, 2006, 108 (07) : 2244 - 2247

[14] Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (01) : 92 - 99

[15] Clopidogrel and Calcium-Channel Antagonists Another Drug-Drug Interaction for the Ever-Wary Clinician? [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (19) : 1564 - 1566

[16] Kurihara A., 2005, DRUG METAB REV S2, V37, P99

[17] Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction [J]. CIRCULATION, 2003, 107 (01) : 32 - 37

[18] Levin L S, 1981, J Md State Dent Assoc, V24, P21

[19] Lins R, 1999, SEMIN THROMB HEMOST, V25, P29

[20] High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients - A Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis [J]. AMERICAN HEART JOURNAL, 2008, 155 (05) : 954 - 958